Beta Bionics to Integrate iLet Bionic Pancreas with Abbott's Future Dual Sensor

Reuters
2025.06.19 11:00

Beta Bionics, Inc. has announced a partnership with Abbott to integrate its iLet Bionic Pancreas with Abbott’s upcoming dual glucose-ketone sensor in the U.S. This collaboration aims to enhance diabetes management by automating insulin dosing and eliminating the need for carb counting. The partnership builds on their existing work with the FreeStyle Libre® 3 Plus sensor, emphasizing their commitment to improving real-time decision-making support for diabetes care.

Beta Bionics, Inc., a leader in advanced diabetes management solutions, has announced a new agreement with Abbott to integrate its iLet Bionic Pancreas with Abbott’s upcoming dual glucose-ketone sensor in the United States. The iLet system, renowned for its fully automated insulin dosing capabilities, aims to enhance diabetes care by eliminating the need for carb counting and manual insulin corrections. This partnership builds on the existing collaboration between Beta Bionics and Abbott, currently supporting the FreeStyle Libre® 3 Plus sensor, and underscores their commitment to advancing real-time decision-making support for people with diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9471250-en) on June 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.